Aliases & Classifications for Paronychia

MalaCards integrated aliases for Paronychia:

Name: Paronychia 12 77 30 56 45 15 17
Paronychia Inflammation 12 74
Onychia and Paronychia of Finger 12
Onychia and Paronychia of Toe 12
Fungal Nail Infection 12
Infected Nailfold 12
Onychomycosis 74

Classifications:



External Ids:

Disease Ontology 12 DOID:13117
MeSH 45 D010304
NCIt 51 C79702
SNOMED-CT 69 71906005
ICD10 34 L03.0

Summaries for Paronychia

Disease Ontology : 12 A nail disease characterized by often-tender bacterial or fungal hand infection or foot infection due to either bacteria or fungus (Candida albicans) where the nail and skin meet at the side or the base of a finger or toe nail. The infection can start suddenly (acute paronychia) or gradually (chronic paronychia). Puss is usually present, along with gradual thickening and browning discoloration of the nail plate.

MalaCards based summary : Paronychia, also known as paronychia inflammation, is related to candidal paronychia and neuropathy, hereditary sensory and autonomic, type iia. An important gene associated with Paronychia is EGFR (Epidermal Growth Factor Receptor), and among its related pathways/superpathways are ERK Signaling and Akt Signaling. The drugs Phylloquinone and Fluorouracil have been mentioned in the context of this disorder. Affiliated tissues include skin, lung and bone, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 77 Paronychia is a nail disease that is an often-tender bacterial or fungal infection of the hand or foot... more...

Related Diseases for Paronychia

Diseases related to Paronychia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 82)
# Related Disease Score Top Affiliating Genes
1 candidal paronychia 12.1
2 neuropathy, hereditary sensory and autonomic, type iia 11.1
3 pemphigus 10.3
4 pyogenic granuloma 10.3
5 pemphigus vulgaris, familial 10.3
6 pemphigus vulgaris 10.3
7 leishmaniasis 10.2
8 cutaneous leishmaniasis 10.2
9 squamous cell carcinoma 10.1
10 dermatitis 10.1
11 luminal breast carcinoma 10.1 EGFR MTOR
12 contact dermatitis 10.1
13 geographic tongue 10.1 EGFR MTOR
14 pulmonary blastoma 10.0 EGFR KRAS
15 mucinous lung adenocarcinoma 10.0 EGFR KRAS
16 adenosquamous lung carcinoma 10.0 EGFR KRAS
17 mucinous adenocarcinoma 10.0 EGFR KRAS
18 bronchiolo-alveolar adenocarcinoma 10.0 EGFR KRAS
19 estrogen-receptor positive breast cancer 10.0 EGFR MTOR
20 lung benign neoplasm 10.0 EGFR KRAS
21 neutropenia 10.0
22 osteomyelitis 10.0
23 allergic contact dermatitis 10.0
24 pyoderma 10.0
25 psoriasis 10.0
26 adenosquamous carcinoma 10.0 EGFR KRAS
27 colonic disease 9.9 EGFR KRAS
28 colorectal adenocarcinoma 9.9 EGFR KRAS
29 endometrial adenocarcinoma 9.9 EGFR KRAS
30 intrahepatic cholangiocarcinoma 9.8 EGFR KRAS
31 autoimmune disease 9.8
32 keloid formation 9.8
33 ocular cicatricial pemphigoid 9.8
34 small cell cancer of the lung 9.8
35 buerger disease 9.8
36 lung cancer 9.8
37 diabetes mellitus 9.8
38 hepatitis 9.8
39 leukemia 9.8
40 nephrolithiasis 9.8
41 fusariosis 9.8
42 lymphoma 9.8
43 pseudopterygium 9.8
44 blastomycosis 9.8
45 balanitis 9.8
46 bronchus cancer 9.8
47 cheilitis 9.8
48 pericarditis 9.8
49 hepatitis c 9.8
50 melanoma 9.8

Graphical network of the top 20 diseases related to Paronychia:



Diseases related to Paronychia

Symptoms & Phenotypes for Paronychia

GenomeRNAi Phenotypes related to Paronychia according to GeneCards Suite gene sharing:

27 (show all 31)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.65 EGFR MTOR KRAS
2 Decreased viability GR00106-A-0 10.65 KRAS
3 Decreased viability GR00221-A-1 10.65 EGFR MTOR KRAS MAP2K7
4 Decreased viability GR00221-A-2 10.65 KRAS
5 Decreased viability GR00221-A-3 10.65 WNK1
6 Decreased viability GR00221-A-4 10.65 EGFR MTOR WNK1
7 Decreased viability GR00301-A 10.65 KRAS
8 Decreased viability GR00342-S-1 10.65 MTOR MAP2K7
9 Decreased viability GR00342-S-2 10.65 MTOR
10 Decreased viability GR00381-A-1 10.65 KRAS
11 Decreased viability GR00402-S-2 10.65 EGFR MTOR WNK1 KRAS MAP2K7
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-117 10.24 KRAS
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-145 10.24 KRAS
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-165 10.24 KRAS
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-173 10.24 MTOR
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-193 10.24 KRAS
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 10.24 KRAS
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-27 10.24 KRAS
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-33 10.24 KRAS WNK1
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 10.24 KRAS MTOR WNK1
21 Decreased shRNA abundance (Z-score < -2) GR00366-A-60 10.24 MTOR
22 Decreased shRNA abundance (Z-score < -2) GR00366-A-66 10.24 KRAS
23 Decreased shRNA abundance (Z-score < -2) GR00366-A-84 10.24 WNK1
24 Decreased viability with paclitaxel GR00179-A-1 9.85 EGFR MTOR
25 Decreased viability with paclitaxel GR00179-A-2 9.85 MTOR
26 Decreased viability with paclitaxel GR00179-A-3 9.85 EGFR MTOR
27 Decreased substrate adherent cell growth GR00193-A-2 9.8 EGFR MAP2K7 MTOR WNK1
28 Decreased substrate adherent cell growth GR00193-A-3 9.8 MAP2K7 WNK1
29 Decreased cell migration GR00055-A-1 9.58 EGFR KRAS MTOR
30 Increased cell migration GR00055-A-3 9.13 EGFR KRAS MTOR
31 shRNA abundance <= 50% GR00343-S 9.1 EGFR KRAS MAP2K7 MTOR SERPINA3 WNK1

MGI Mouse Phenotypes related to Paronychia:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 muscle MP:0005369 9.26 EGFR KRAS MTOR WNK1
2 renal/urinary system MP:0005367 8.92 EGFR KRAS MTOR WNK1

Drugs & Therapeutics for Paronychia

Drugs for Paronychia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 105)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Phylloquinone Approved, Investigational Phase 4 84-80-0
2
Fluorouracil Approved Phase 4,Phase 2 51-21-8 3385
3
Cetuximab Approved Phase 4 205923-56-4 56842117 2333
4
leucovorin Approved Phase 4,Phase 2 58-05-9 6006 143
5
Irinotecan Approved, Investigational Phase 4,Phase 2 100286-90-6, 97682-44-5 60838
6
afatinib Approved Phase 4 850140-72-6, 439081-18-2 10184653
7
Amorolfine Approved, Investigational Phase 4 78613-35-1
8
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
9
Menadione Approved, Nutraceutical Phase 4 58-27-5 4055
10
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2 59-30-3 6037
11 Immunoglobulins Phase 4
12 Antibodies, Monoclonal Phase 4
13 Antineoplastic Agents, Immunological Phase 4,Phase 2
14 Vitamin B Complex Phase 4,Phase 2
15 naphthoquinone Phase 4
16 Vitamin K Phase 4
17 Vitamins Phase 4,Phase 2
18 Antibodies Phase 4
19 Vitamin B9 Phase 4,Phase 2
20 Folate Phase 4,Phase 2
21 Menaquinone Phase 4
22 Mitogens Phase 4,Not Applicable
23 Vitamin K 1 Phase 4
24 Anti-Infective Agents Phase 4,Phase 2,Not Applicable
25 Protein Kinase Inhibitors Phase 4,Phase 2
26 Antifungal Agents Phase 4
27
Panitumumab Approved, Investigational Phase 2 339177-26-3 50070211
28
Hydrocortisone Approved, Vet_approved Phase 2 50-23-7 5754
29
Ciprofloxacin Approved, Investigational Phase 2 85721-33-1 2764
30
Hydroxyzine Approved Phase 2 68-88-2 3658
31
Clavulanate Approved, Vet_approved Phase 2 58001-44-8 5280980
32
Silver sulfadiazine Approved, Vet_approved Phase 2 22199-08-2 441244
33
Petrolatum Approved, Investigational Phase 2 8009-03-8
34
Clindamycin Approved, Vet_approved Phase 2 18323-44-9 29029
35
Sulfadiazine Approved, Investigational, Vet_approved Phase 2 68-35-9 5215
36
Doxycycline Approved, Investigational, Vet_approved Phase 2 564-25-0 54671203
37
Amoxicillin Approved, Vet_approved Phase 2,Not Applicable 26787-78-0 33613
38
Hydrocortisone acetate Approved, Vet_approved Phase 2 50-03-3
39
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
40
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
41
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
42
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
43
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 6857599 5310940 9887054 43805
44
Levoleucovorin Approved, Investigational Phase 2 68538-85-2
45
Decitabine Approved, Investigational Phase 2 2353-33-5 451668
46
Azacitidine Approved, Investigational Phase 2 320-67-2 9444
47 Tomato Approved Phase 2
48 Lycopene Approved, Investigational Phase 2 502-65-8 53477748
49
Calcium Approved, Nutraceutical Phase 2 7440-70-2 271
50
Prednisolone hemisuccinate Experimental Phase 2 2920-86-7

Interventional clinical trials:

(show all 16)
# Name Status NCT ID Phase Drugs
1 FOLFIRI in Combination With Cetuximab in the First-line Treatment of Metastatic Colorectal Cancer Including a Regular Dermal Prophylaxis to Prevent Acneiforme Follicular Exanthema Unknown status NCT01315990 Phase 4 FOLFIRI + Cetuximab
2 A Pilot Study - Safety and Efficacy of Nailprotex® for Onychomycosis Treatment Completed NCT02464826 Phase 4 Nailprotex
3 Comparison Between Long-pulsed Nd:YAG, Amorolfine and Combination Treatment in Treating Non-dermatophyte Onychomycosis Recruiting NCT02812043 Phase 4 Amorolfine
4 Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older Active, not recruiting NCT02514174 Phase 4 Afatinib
5 Afatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status (ECOG 2 or 3) Terminated NCT02695290 Phase 4 Afatinib
6 A Trial to Evaluate the Efficacy and Safety of Two Concentrations of VBP-926 Solution for the Treatment of Chemotherapy-associated Paronychia in Cancer Patients Completed NCT03207906 Phase 2 VBP-926
7 Skin Toxicity Treatment in Metastatic Colorectal Cancer (mCRC) Patients Receiving Panitumumab + Irinotecan-based Therapy Completed NCT00332163 Phase 2 Irinotecan;FOLFIRI;Pre-emptive Skin Treatment;Reactive Skin Treatment
8 Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO Completed NCT01465802 Phase 2 Dacomitinib;Dacomitinib;Doxycycline;Probiotic;Alclometasone cream
9 A Study of Management of Tarceva - Induced Rash in Patients With Non-Small Cell Lung Cancer. Completed NCT00531934 Phase 2 Doxycline;erlotinib [Tarceva]
10 Safety and Efficacy Study of mFOLFOX6 + Panitumumab Combination Therapy and 5-FU/LV + Panitumumab Combination Therapy in Participants With Chemotherapy-naïve Unresectable Advanced Recurrent Colorectal Carcinoma Completed NCT02337946 Phase 2 oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab;oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab
11 An Efficacy and Safety Study of Decitabine in Participants With Myelodysplastic Syndrome (MDS) Completed NCT00744757 Phase 2 Decitabine
12 Panitumumab Skin Toxicity Prevention Trial Recruiting NCT03167268 Phase 2 Lycopene
13 Preventive Effect of EGF Cream for Cutaneous Adverse Event of EGFR Inhibitors Unknown status NCT03051880 Not Applicable Repair Control EGF®;Cream without rhEGF
14 Impact of Antibiotic Treatment of Group A Streptococcal Blistering Distal Dactylitis in Children Completed NCT02624882 Not Applicable
15 GIOTRIF in First Line Therapy of Advanced NSCLC With EGFR-mutations Completed NCT02047903 Afatinib
16 An Observational Study of Erlotinib Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer Completed NCT01782690 erlotinib;gemcitabine

Search NIH Clinical Center for Paronychia

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: paronychia

Genetic Tests for Paronychia

Genetic tests related to Paronychia:

# Genetic test Affiliating Genes
1 Paronychia 30

Anatomical Context for Paronychia

MalaCards organs/tissues related to Paronychia:

42
Skin, Lung, Bone, Testes, Breast, T Cells

Publications for Paronychia

Articles related to Paronychia:

(show top 50) (show all 238)
# Title Authors Year
1
Paronychia Associated with Ledipasvir/Sofosbuvir for Hepatitis C Treatment. ( 30881576 )
2019
2
Mucous membrane pemphigoid-associated paronychia with onychomadesis. ( 30674299 )
2019
3
Chronic paronychia with subungual purpura. ( 30829296 )
2019
4
Are topical beta-blockers really effective "in real life" for targeted therapy-induced paronychia. ( 30847700 )
2019
5
Topical Betaxolol for Treating Relapsing Paronychia with Pyogenic Granuloma-Like Lesions Induced by Epidermal Growth Factor Receptor Inhibitors. ( 29339238 )
2018
6
Febrile neutropenia with bacterial paronychia. ( 29531738 )
2018
7
Using a novel scoring system for paronychia related to oncologic treatments (SPOT) for assessing paronychia severity and its correlation with pain index and quality of life. ( 29894010 )
2018
8
Topical Timolol for Paronychia and Pseudopyogenic Granuloma in Patients Treated With Epidermal Growth Factor Receptor Inhibitors and Capecitabine. ( 29117285 )
2018
9
Relationship between Paronychia and Drug Concentrations of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. ( 29902802 )
2018
10
Chronic Paronychia and Onychomadesis in Pemphigus Vegetans: An Unusual Presentation in a Rare Autoimmune Disease. ( 29560011 )
2018
11
Purulent Pericarditis Due to Paronychia in a 16-Month-Old Child: A Nail-Biting Story. ( 29506451 )
2018
12
Retronychia a little-known cause of paronychia: A report of two cases in adolescent patients. ( 29479729 )
2018
13
Systemic Drug-induced Chronic Paronychia and Periungual Pyogenic Granuloma. ( 30258794 )
2018
14
Papulopustules and paronychia in a lung carcinoma. ( 30297249 )
2018
15
Case series showing the efficacy of 5-aminolaevulinic acid photodynamic therapy for epidermal growth factor receptor inhibitor-induced paronychia and pyogenic granuloma-like lesions. ( 30298920 )
2018
16
A Proposal for a New Severity Index for the Evaluation of Chronic Paronychia. ( 30643778 )
2018
17
Recurrent Paronychia as a Presenting Manifestation of Pemphigus Vulgaris: A Case Report. ( 28611998 )
2017
18
Acute and Chronic Paronychia. ( 28671378 )
2017
19
Nail Braces for Severe Paronychia Induced by Epidermal Growth Factor Receptor Inhibitors: An alternative to nail extraction. ( 28987490 )
2017
20
Primary Cutaneous CD8+ T-cell Lymphoma, an Indolent and Locally Aggressive Form Mimicking Paronychia. ( 28984695 )
2017
21
Neonatal Acute Paronychia. ( 28720045 )
2017
22
Paronychia: What You Should Know. ( 28671380 )
2017
23
Chinese Medicine Treatment for Afatinib-Induced Paronychia. ( 28948057 )
2017
24
Paronychia with Sporangium Formation Causing an Ingrown Toenail A Rare Case Report. ( 29116824 )
2017
25
Chemotherapy-associated paronychia treated with 2% povidone-iodine: a series of cases. ( 28721095 )
2017
26
Pediatric Dermatology Photoquiz: Refractory Purulent Paronychia in a Young Girl. Paronychial cutaneous leishmaniasis. ( 26758096 )
2016
27
Acute felon and paronychia: Antibiotics not necessary after surgical treatment. Prospective study of 46 patients. ( 27117023 )
2016
28
Paronychia and granulation tissue formation during treatment with isotretinoin. ( 27192525 )
2016
29
Toenail paronychia. ( 27810017 )
2016
30
Non-healing ulcerative paronychia. ( 28017401 )
2016
31
sQuiz your knowledge: chronic paronychia of the third toe. ( 27241472 )
2016
32
Periungual Abscess Caused by Citrobacter braakii in a Patient with Chronic Paronychia. ( 27489449 )
2016
33
sQUIZ your knowledge: Chronic paronychia of the third toe. ( 27789424 )
2016
34
Paronychia and onychomadesis due to pemphigus vulgaris. ( 27506502 )
2016
35
Chronic paronychia treatment: Square flap technique. ( 26946988 )
2016
36
Paronychia-like digital metastases of osteosarcoma. ( 27495265 )
2016
37
Congenital Malalignment of the Great Toenails With Acute Paronychia. ( 27396767 )
2016
38
Ungual squamous cell carcinoma mimicking a chronic paronychia: clinical, pathological and radiological correlation. ( 26632936 )
2015
39
Chemotherapy-associated paronychia treated with a dilute povidone-iodine/dimethylsulfoxide preparation. ( 26445556 )
2015
40
Evaluation of role of Candida in patients with chronic paronychia. ( 26087081 )
2015
41
HPLC-UV/DAD and ESI-MS(n) analysis of flavonoids and antioxidant activity of an Algerian medicinal plant: Paronychia argentea Lam. ( 25910047 )
2015
42
Tips to Treat the 5 Most Common Nail Disorders: Brittle Nails, Onycholysis, Paronychia, Psoriasis, Onychomycosis. ( 25828710 )
2015
43
Effective treatments for paronychia caused by oncology pharmacotherapy. ( 26596962 )
2015
44
Antibiotic Overuse and Paronychia: A Teachable Moment. ( 26569127 )
2015
45
Paronychia-like cutaneous leishmaniasis. ( 26632940 )
2015
46
Treatment and prevention of paronychia using a new combination of topicals: 30 cases report. ( 25854670 )
2015
47
Case of Fusarium paronychia successfully treated with occlusive dressing of antifungal cream. ( 24533442 )
2014
48
Management of chronic paronychia. ( 24470654 )
2014
49
Oleanane type glycosides from Paronychia anatolica subsp. balansae. ( 24321579 )
2014
50
Images in clinical medicine. Cutaneous leishmaniasis with a paronychia-like lesion. ( 25354107 )
2014

Variations for Paronychia

Expression for Paronychia

Search GEO for disease gene expression data for Paronychia.

Pathways for Paronychia

Pathways related to Paronychia according to GeneCards Suite gene sharing:

(show all 50)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.56 EGFR KRAS MAP2K7 MTOR WNK1
2
Show member pathways
13.15 EGFR KRAS MTOR WNK1
3
Show member pathways
12.96 EGFR KRAS MAP2K7 MTOR
4
Show member pathways
12.69 EGFR KRAS MAP2K7 MTOR
5
Show member pathways
12.69 EGFR KRAS MAP2K7 MTOR
6 12.61 EGFR KRAS MTOR
7
Show member pathways
12.58 KRAS MAP2K7 MTOR
8
Show member pathways
12.54 EGFR KRAS MTOR
9 12.54 EGFR KRAS MAP2K7
10
Show member pathways
12.53 EGFR KRAS MAP2K7 MTOR
11
Show member pathways
12.5 EGFR KRAS MTOR
12
Show member pathways
12.49 KRAS MAP2K7 MTOR
13
Show member pathways
12.46 EGFR KRAS MAP2K7
14
Show member pathways
12.33 EGFR KRAS MAP2K7 MTOR
15 12.31 EGFR KRAS MTOR
16
Show member pathways
12.29 EGFR KRAS MTOR
17
Show member pathways
12.26 EGFR KRAS MAP2K7 MTOR
18
Show member pathways
12.22 EGFR KRAS MTOR
19
Show member pathways
12.21 EGFR KRAS MAP2K7
20
Show member pathways
12.21 KRAS MAP2K7 MTOR
21
Show member pathways
12.19 EGFR KRAS MTOR
22
Show member pathways
12.19 EGFR KRAS MTOR
23
Show member pathways
12.11 EGFR KRAS MAP2K7 MTOR
24 12.06 EGFR KRAS MTOR
25
Show member pathways
12.05 EGFR KRAS MAP2K7 MTOR
26
Show member pathways
12.03 KRAS MAP2K7 MTOR
27
Show member pathways
12 EGFR KRAS MAP2K7
28
Show member pathways
11.99 EGFR KRAS MTOR
29 11.95 EGFR KRAS MTOR
30 11.91 EGFR KRAS MTOR
31 11.9 EGFR KRAS MTOR
32
Show member pathways
11.88 EGFR KRAS MAP2K7
33
Show member pathways
11.86 EGFR KRAS MTOR
34
Show member pathways
11.78 EGFR KRAS MTOR
35 11.63 EGFR KRAS MTOR
36 11.6 EGFR KRAS MTOR
37 11.57 EGFR KRAS
38 11.51 EGFR MTOR
39 11.43 EGFR KRAS
40 11.38 EGFR MAP2K7
41 11.35 EGFR KRAS
42 11.31 EGFR KRAS MTOR
43 11.3 EGFR KRAS
44 11.17 KRAS MTOR
45 11.11 KRAS MTOR
46 11.04 EGFR KRAS
47 10.84 EGFR KRAS MAP2K7 MTOR
48 10.69 EGFR MAP2K7
49 10.61 EGFR KRAS MTOR
50
Show member pathways
10.21 EGFR KRAS MTOR

GO Terms for Paronychia

Biological processes related to Paronychia according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 phosphorylation GO:0016310 9.56 EGFR MAP2K7 MTOR WNK1
2 liver development GO:0001889 9.49 EGFR KRAS
3 peptidyl-threonine phosphorylation GO:0018107 9.48 MTOR WNK1
4 positive regulation of MAP kinase activity GO:0043406 9.46 EGFR KRAS
5 positive regulation of smooth muscle cell proliferation GO:0048661 9.43 EGFR MTOR
6 cellular response to amino acid stimulus GO:0071230 9.4 EGFR MTOR
7 visual learning GO:0008542 9.37 KRAS MTOR
8 positive regulation of protein phosphorylation GO:0001934 9.33 EGFR KRAS MTOR
9 response to osmotic stress GO:0006970 9.32 EGFR MAP2K7
10 protein phosphorylation GO:0006468 9.26 EGFR MAP2K7 MTOR WNK1
11 protein autophosphorylation GO:0046777 8.8 EGFR MTOR WNK1

Molecular functions related to Paronychia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ATP binding GO:0005524 9.67 EGFR MAP2K7 MTOR WNK1
2 protein serine/threonine kinase activity GO:0004674 9.5 MAP2K7 MTOR WNK1
3 kinase activity GO:0016301 9.46 EGFR MAP2K7 MTOR WNK1
4 nucleotide binding GO:0000166 9.43 EGFR KRAS MTOR
5 protein phosphatase binding GO:0019903 9.4 EGFR MAP2K7
6 protein kinase activity GO:0004672 9.26 EGFR MAP2K7 MTOR WNK1
7 protein kinase binding GO:0019901 8.92 EGFR MAP2K7 MTOR WNK1

Sources for Paronychia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....